



SHUKRA

PHARMACEUTICALS LTD.

18th May, 2024

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on **29th May 2024**, Wednesday at the Registered Office of the Company *inter alia* to consider and approve the following: -

1. To Consider, Adopt and Approve Audited financial result for the quarter and financial year ended on 31st March, 2024 along with the Auditor's Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
2. Recommend final dividend to the members of the company for the financial year 2023-24
3. Any other business with the permission of Chairman.

In terms of the Company's Code of Conduct for Prevention of Insider Trading, the "Trading Window" for dealing in securities of the Company has been closed from 1ST April 2024 till the end of 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended on March 31, 2024.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
DIN: 08316893

CIN : L24231GJ1993PLC019079